Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1256 Neoplasms 1074 Carcinoma, Non-Small-Cell Lung 874 Prostatic Neoplasms 714 Lung Neoplasms 596 Colorectal Neoplasms 590 Neoplasm Metastasis 452 Multiple Myeloma 432 Leukemia, Myeloid, Acute 423 Pancreatic Neoplasms 370 Ovarian Neoplasms 367 Melanoma 324 Carcinoma, Hepatocellular 299 Squamous Cell Carcinoma of Head and Neck 276 Brain Neoplasms 275 Recurrence 273 Stomach Neoplasms 245 Head and Neck Neoplasms 241 Glioblastoma 239 Carcinoma, Renal Cell 227 Lymphoma 226 Triple Negative Breast Neoplasms 225 Precursor Cell Lymphoblastic Leukemia-Lymphoma 222 Hematologic Neoplasms 212 Urinary Bladder Neoplasms 211 Uterine Cervical Neoplasms 200 Endometrial Neoplasms 199 Sarcoma 195 Glioma 194 Lymphoma, Non-Hodgkin 188

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × 90 days × Clear all

NCT05295992 2026-03-06

ARTIA-Vesica

Varian, a Siemens Healthineers Company

Phase NA Active not recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡